You are here

ALFQ Adjuvant

In the 1990s, MHRP developed a family of new adjuvants called the Army Liposome Formulation (ALF), and the ALFQ was awarded a patent in late 2019. Adjuvants are vaccine components that help activate the immune system and improve immune responses. MHRP will be evaluating the effect of these promising new compounds on vaccine responses in various HIV vaccine clinical trials in Kenya and Thailand in 2020. It will also be tested with vaccines for malaria, enteric diseases and heroin.